Product Center
Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine for Children Aged 6-35 Months Accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28
- Views:
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine for Children Aged 6-35 Months Accepted!
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28 10:17
- Views:
On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Source: Center for Drug Evaluation of the National Medical Products Administration
At present, the influenza virus remains one of the most important respiratory pathogens threatening public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of the influenza virus have significant impacts on human health and socioeconomic development. Especially for infants, the elderly, and patients with underlying cardiovascular and pulmonary diseases, infection with the influenza virus may lead to serious complications such as pneumonia, potentially resulting in severe illness or death. Currently, getting vaccinated against influenza is the most effective measure to prevent influenza infection and pandemics.
The acceptance of this marketing application for the quadrivalent influenza virus subunit vaccine for children aged 6-35 months is another significant milestone for Ab&B Bio's subunit influenza vaccine portfolio. The vaccine has completed Phase III clinical trials and met the expected endpoints. This high-quality vaccine, which combines high purity, low adverse effects, good safety, and comprehensive protection, will become China's first universally applicable quadrivalent influenza virus subunit vaccine for all age groups! It is expected to be approved for market launch in 2025! Ab&B Bio will continue to work diligently to achieve the launch of multiple products, safeguarding human life and health!
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
